;PMID: 3015692
;source_file_908.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)sentence:[e:39..104] = [t:39..104]
;2)section:[e:108..134] = [t:108..134]
;3)sentence:[e:138..252] = [t:138..252]
;4)sentence:[e:253..308] = [t:253..308]
;5)sentence:[e:309..401] = [t:309..401]
;6)sentence:[e:402..563] = [t:402..563]
;7)sentence:[e:564..677] = [t:564..677]
;8)sentence:[e:678..801] = [t:678..801]
;9)sentence:[e:802..977] = [t:802..977]
;10)sentence:[e:978..1115] = [t:978..1115]
;11)sentence:[e:1116..1172] = [t:1116..1172]
;12)sentence:[e:1173..1304] = [t:1173..1304]
;13)sentence:[e:1305..1432] = [t:1305..1432]
;14)sentence:[e:1433..1643] = [t:1433..1643]
;15)section:[e:1647..1665] = [t:1647..1665]
;16)section:[e:1671..1677] = [t:1671..1677]
;17)section:[e:1681..1725] = [t:1681..1725]
;Token/POS Errors
;ERROR_POS mismatch [133..134] t:token e:. .
;ERROR_POS mismatch [1724..1725] t:token e:-RRB- ]

;section 0 Span:0..33
;Fed Proc. 1986 Aug;45(9):2376-81.
(SEC
  (FRAG (NNP:[0..3] Fed) (NNP:[4..8] Proc) (.:[8..9] .) (CD:[10..14] 1986)
        (NNP:[15..18] Aug) (NN:[18..19] ;) (CD:[19..21] 45) (NN:[21..22] -LRB-)
        (CD:[22..23] 9) (NN:[23..24] -RRB-) (::[24..25] :) (CD:[25..29] 2376)
        (::[29..30] -) (CD:[30..32] 81) (.:[32..33] .)))

;sentence 1 Span:39..104
;Inhibition of aldosterone synthesis by atrial natriuretic factor.
;[53..64]:substance:"aldosterone"
;[78..103]:substance:"atrial natriuretic factor"
(SENT
  (NP-HLN
    (NP (NN:[39..49] Inhibition))
    (PP (IN:[50..52] of)
      (NP (NN:[53..64] aldosterone) (NN:[65..74] synthesis)))
    (PP (IN:[75..77] by)
      (NP (JJ:[78..84] atrial) (JJ:[85..96] natriuretic) (NN:[97..103] factor)))
    (.:[103..104] .)))

;section 2 Span:108..134
;Elliott ME, Goodfriend TL.
(SEC
  (FRAG (NNP:[108..115] Elliott) (NNP:[116..118] ME) (,:[118..119] ,)
        (NNP:[120..130] Goodfriend) (NNP:[131..133] TL) (token:[133..134] .)))

;sentence 3 Span:138..252
;Atrial natriuretic factor (ANF) inhibits basal and stimulated aldosterone 
;synthesis in adrenal glomerulosa cells.
;[138..163]:substance:"Atrial natriuretic factor"
;[165..168]:substance:"ANF"
;[200..211]:substance:"aldosterone"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[138..144] Atrial) (JJ:[145..156] natriuretic)
          (NN:[157..163] factor))
      (NP (-LRB-:[164..165] -LRB-) (NN:[165..168] ANF) (-RRB-:[168..169] -RRB-)))
    (VP (VBZ:[170..178] inhibits)
      (NP
        (NP (JJ:[179..184] basal)
          (NML-1 (-NONE-:[184..184] *P*)))
        (CC:[185..188] and)
        (NP (JJ:[189..199] stimulated)
          (NML-1 (NN:[200..211] aldosterone) (NN:[213..222] synthesis))))
      (PP-LOC (IN:[223..225] in)
        (NP (JJ:[226..233] adrenal) (NN:[234..245] glomerulosa)
            (NNS:[246..251] cells))))
    (.:[251..252] .)))

;sentence 4 Span:253..308
;ANF probably acts through specific  membrane receptors.
;[253..256]:substance:"ANF"
;[298..307]:substance:"receptors"
(SENT
  (S
    (NP-SBJ (NN:[253..256] ANF))
    (ADVP (RB:[257..265] probably))
    (VP (VBZ:[266..270] acts)
      (PP (IN:[271..278] through)
        (NP (JJ:[279..287] specific) (NN:[289..297] membrane)
            (NNS:[298..307] receptors))))
    (.:[307..308] .)))

;sentence 5 Span:309..401
;Alterations in cyclic GMP and cyclic AMP levels do not  account for ANF's
;inhibitory effect.
;[324..334]:substance:"cyclic GMP"
;[339..349]:substance:"cyclic AMP"
;[377..380]:substance:"ANF"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[309..320] Alterations))
      (PP (IN:[321..323] in)
        (NP
          (NP
             (JJ:[324..330] cyclic) (NN:[331..334] GMP)
            (NML-1 (-NONE-:[334..334] *P*)))
          (CC:[335..338] and)
          (NP
             (JJ:[339..345] cyclic) (NN:[346..349] AMP)
            (NML-1 (NNS:[350..356] levels))))))
    (VP (VBP:[357..359] do) (RB:[360..363] not)
      (VP (VB:[365..372] account)
        (PP-CLR (IN:[373..376] for)
          (NP
            (NP (NN:[377..380] ANF) (POS:[380..382] 's))
            (JJ:[383..393] inhibitory) (NN:[394..400] effect)))))
    (.:[400..401] .)))

;sentence 6 Span:402..563
;ANF does not block angiotensin II (AngII)  receptors nor does it interfere
;with phosphoinositide metabolism or calcium  movements stimulated by adrenal
;agonists.
;[402..405]:substance:"ANF"
;[421..454]:substance:"angiotensin II (AngII)  receptors"
;[482..498]:substance:"phosphoinositide"
;[513..520]:substance:"calcium"
;[554..562]:substance:"agonists"
(SENT
  (S
    (S
      (NP-SBJ (NN:[402..405] ANF))
      (VP (VBZ:[406..410] does) (RB:[411..414] not)
        (VP (VB:[415..420] block)
          (NP
            (NML
              (NML (NN:[421..432] angiotensin) (CD:[433..435] II))
              (NML (-LRB-:[436..437] -LRB-) (NN:[437..442] AngII)
                   (-RRB-:[442..443] -RRB-)))
            (NNS:[445..454] receptors)))))
    (CC:[455..458] nor)
    (SINV (VBZ:[459..463] does)
      (NP-SBJ (PRP:[464..466] it))
      (VP (VB:[467..476] interfere)
        (PP-CLR (IN:[477..481] with)
          (NP
            (NP (NN:[482..498] phosphoinositide) (NN:[499..509] metabolism))
            (CC:[510..512] or)
            (NP
              (NP (NN:[513..520] calcium) (NNS:[522..531] movements))
              (VP (VBN:[532..542] stimulated)
                (NP (-NONE-:[542..542] *))
                (PP (IN:[543..545] by)
                  (NP-LGS (JJ:[546..553] adrenal) (NNS:[554..562] agonists)))))))))
    (.:[562..563] .)))

;sentence 7 Span:564..677
;ANF does not inhibit protein synthesis  nor does it work by inhibiting
;NA+,K+-ATPase or depleting cell potassium.
;[564..567]:substance:"ANF"
;[585..592]:substance:"protein"
;[635..638]:substance:"NA+"
;[639..648]:substance:"K+-ATPase"
;[667..676]:substance:"potassium"
(SENT
  (UCP
    (S
      (NP-SBJ (NN:[564..567] ANF))
      (VP (VBZ:[568..572] does) (RB:[573..576] not)
        (VP (VB:[577..584] inhibit)
          (NP (NN:[585..592] protein) (NN:[593..602] synthesis)))))
    (CC:[604..607] nor)
    (SINV (VBZ:[608..612] does)
      (NP-SBJ (PRP:[613..615] it))
      (VP (VB:[616..620] work)
        (PP (IN:[621..623] by)
          (S-NOM
            (S
              (NP-SBJ (-NONE-:[623..623] *))
              (VP (VBG:[624..634] inhibiting)
                (NP
                  (NML (NN:[635..637] NA) (SYM:[637..638] +))
                  (,:[638..639] ,)
                  
                  (NML (NN:[639..640] K) (SYM:[640..641] +))
                  (HYPH:[641..642] -) (NN:[642..648] ATPase))))
            (CC:[649..651] or)
            (S
              (NP-SBJ (-NONE-:[651..651] *))
              (VP (VBG:[652..661] depleting)
                (NP (NN:[662..666] cell) (NN:[667..676] potassium))))))))
    (.:[676..677] .)))

;sentence 8 Span:678..801
;ANF  decreases conversion of endogenous cholesterol to pregnenolone, the step
; stimulated by adrenocorticotropin and AngII.
;[678..681]:substance:"ANF"
;[718..729]:substance:"cholesterol"
;[733..745]:substance:"pregnenolone"
;[771..790]:substance:"adrenocorticotropin"
;[795..800]:substance:"AngII"
(SENT
  (S
    (NP-SBJ (NN:[678..681] ANF))
    (VP (VBZ:[683..692] decreases)
      (NP
        (NP
          (NP (NN:[693..703] conversion))
          (PP (IN:[704..706] of)
            (NP (JJ:[707..717] endogenous) (NN:[718..729] cholesterol)))
          (PP (TO:[730..732] to)
            (NP (NN:[733..745] pregnenolone))))
        (,:[745..746] ,)
        (NP
          (NP (DT:[747..750] the) (NN:[751..755] step))
          (VP (VBN:[757..767] stimulated)
            (NP (-NONE-:[767..767] *))
            (PP (IN:[768..770] by)
              (NP-LGS (NN:[771..790] adrenocorticotropin) (CC:[791..794] and)
                      (NN:[795..800] AngII)))))))
    (.:[800..801] .)))

;sentence 9 Span:802..977
;ANF does not affect the conversion  of 20-alpha-hydroxycholesterol, which
;easily penetrates mitochondrial membranes  to the site of the cholesterol
;side-chain cleavage enzyme.
;[802..805]:substance:"ANF"
;[841..868]:substance:"20-alpha-hydroxycholesterol"
;[938..976]:cyp450:"cholesterol side-chain cleavage enzyme"
(SENT
  (S
    (NP-SBJ (NN:[802..805] ANF))
    (VP (VBZ:[806..810] does) (RB:[811..814] not)
      (VP (VB:[815..821] affect)
        (NP
          (NP (DT:[822..825] the) (NN:[826..836] conversion))
          (PP (IN:[838..840] of)
            (NP
              (NP (NN:[841..868] 20-alpha-hydroxycholesterol))
              (,:[868..869] ,)
              (SBAR
                (WHNP-1 (WDT:[870..875] which))
                (S
                  (NP-SBJ-1 (-NONE-:[875..875] *T*))
                  (ADVP (RB:[876..882] easily))
                  (VP (VBZ:[883..893] penetrates)
                    (NP (JJ:[894..907] mitochondrial) (NNS:[908..917] membranes))
                    (PP (TO:[919..921] to)
                      (NP
                        (NP (DT:[922..925] the) (NN:[926..930] site))
                        (PP (IN:[931..933] of)
                          (NP (DT:[934..937] the)
                             (NN:[938..949] cholesterol)
                            (NML
                              (NML (NN:[950..954] side) (HYPH:[954..955] -)
                                   (NN:[955..960] chain))
                              (NN:[961..969] cleavage))
                            (NN:[970..976] enzyme)))))))))))))
    (.:[976..977] .)))

;sentence 10 Span:978..1115
;These results suggest  that ANF inhibits the ability of endogenous
;cholesterol to reach or interact  with the side-chain cleavage enzyme.
;[1006..1009]:substance:"ANF"
;[1045..1056]:substance:"cholesterol"
;[1088..1114]:substance:"side-chain cleavage enzyme"
(SENT
  (S
    (NP-SBJ (DT:[978..983] These) (NNS:[984..991] results))
    (VP (VBP:[992..999] suggest)
      (SBAR (IN:[1001..1005] that)
        (S
          (NP-SBJ (NN:[1006..1009] ANF))
          (VP (VBZ:[1010..1018] inhibits)
            (NP
              (NP (DT:[1019..1022] the) (NN:[1023..1030] ability)
                (S-2 (-NONE-:[1030..1030] *ICH*)))
              (PP (IN:[1031..1033] of)
                (NP (JJ:[1034..1044] endogenous) (NN:[1045..1056] cholesterol)))
              (S-2
                (NP-SBJ (-NONE-:[1056..1056] *))
                (VP (TO:[1057..1059] to)
                  (VP
                    (VP (VB:[1060..1065] reach)
                      (NP-1 (-NONE-:[1065..1065] *RNR*)))
                    (CC:[1066..1068] or)
                    (VP (VB:[1069..1077] interact)
                      (PP (IN:[1079..1083] with)
                        (NP-1 (-NONE-:[1083..1083] *RNR*))))
                    (NP-1 (DT:[1084..1087] the)
                      
                      (NML
                        (NML (NN:[1088..1092] side) (HYPH:[1092..1093] -)
                             (NN:[1093..1098] chain))
                        (NN:[1099..1107] cleavage))
                      (NN:[1108..1114] enzyme))))))))))
    (.:[1114..1115] .)))

;sentence 11 Span:1116..1172
;ANF does not act like a calcium  channel-blocking agent.
;[1116..1119]:substance:"ANF"
;[1140..1147]:substance:"calcium"
;[1166..1171]:substance:"agent"
(SENT
  (S
    (NP-SBJ (NN:[1116..1119] ANF))
    (VP (VBZ:[1120..1124] does) (RB:[1125..1128] not)
      (VP (VB:[1129..1132] act)
        (PP (IN:[1133..1137] like)
          (NP (DT:[1138..1139] a)
            (ADJP
              (NML (NN:[1140..1147] calcium) (NN:[1149..1156] channel))
              (HYPH:[1156..1157] -) (VBG:[1157..1165] blocking))
            (NN:[1166..1171] agent)))))
    (.:[1171..1172] .)))

;sentence 12 Span:1173..1304
;However, ANF is less effective at high-calcium  concentrations, which
;suggests that it may inhibit a step that calcium  stimulates.
;[1182..1185]:substance:"ANF"
;[1212..1219]:substance:"calcium"
;[1284..1291]:substance:"calcium"
(SENT
  (S
    (ADVP (RB:[1173..1180] However))
    (,:[1180..1181] ,)
    (NP-SBJ (NN:[1182..1185] ANF))
    (VP (VBZ:[1186..1188] is)
      (NP-PRD
        (NP (RBR:[1189..1193] less) (JJ:[1194..1203] effective))
        (PP (IN:[1204..1206] at)
          (NP
            (ADJP (JJ:[1207..1211] high) (HYPH:[1211..1212] -)
                  (NN:[1212..1219] calcium))
            (NNS:[1221..1235] concentrations))))
      (,:[1235..1236] ,)
      (SBAR-ADV
        (WHNP-2 (WDT:[1237..1242] which))
        (S
          (NP-SBJ-2 (-NONE-:[1242..1242] *T*))
          (VP (VBZ:[1243..1251] suggests)
            (SBAR (IN:[1252..1256] that)
              (S
                (NP-SBJ (PRP:[1257..1259] it))
                (VP (MD:[1260..1263] may)
                  (VP (VB:[1264..1271] inhibit)
                    (NP
                      (NP (DT:[1272..1273] a) (NN:[1274..1278] step))
                      (SBAR
                        (WHNP-1 (IN:[1279..1283] that))
                        (S
                          (NP-SBJ (NN:[1284..1291] calcium))
                          (VP (VBZ:[1293..1303] stimulates)
                            (NP-1 (-NONE-:[1303..1303] *T*))))))))))))))
    (.:[1303..1304] .)))

;sentence 13 Span:1305..1432
;Understanding ANF action will probably require identification of the 
;specific biochemical changes (mediators) that it induces.
;[1319..1322]:substance:"ANF"
;[1405..1414]:substance:"mediators"
(SENT
  (S
    (S-NOM-SBJ
      (NP-SBJ (-NONE-:[1305..1305] *))
      (VP (VBG:[1305..1318] Understanding)
        (NP (NN:[1319..1322] ANF) (NN:[1323..1329] action))))
    (VP (MD:[1330..1334] will)
      (ADVP (RB:[1335..1343] probably))
      (VP (VB:[1344..1351] require)
        (NP
          (NP (NN:[1352..1366] identification))
          (PP (IN:[1367..1369] of)
            (NP
              (NP (DT:[1370..1373] the) (JJ:[1375..1383] specific)
                  (JJ:[1384..1395] biochemical) (NNS:[1396..1403] changes)
                (PRN (-LRB-:[1404..1405] -LRB-)
                  (NP (NNS:[1405..1414] mediators))
                  (-RRB-:[1414..1415] -RRB-)))
              (SBAR
                (WHNP-1 (WDT:[1416..1420] that))
                (S
                  (NP-SBJ (PRP:[1421..1423] it))
                  (VP (VBZ:[1424..1431] induces)
                    (NP-1 (-NONE-:[1431..1431] *T*))))))))))
    (.:[1431..1432] .)))

;sentence 14 Span:1433..1643
;Parallel efforts to  understand how other agents stimulate steroidogenesis
;(particularly in the areas  of protein synthesis, protein phosphorylation,
;and cholesterol movements) will  further this understanding.
;[1475..1481]:substance:"agents"
;[1539..1546]:substance:"protein"
;[1558..1565]:substance:"protein"
;[1587..1598]:substance:"cholesterol"
(SENT
  (S
    (NP-SBJ (JJ:[1433..1441] Parallel) (NNS:[1442..1449] efforts)
      (S
        (NP-SBJ (-NONE-:[1449..1449] *))
        (VP (TO:[1450..1452] to)
          (VP (VB:[1454..1464] understand)
            (SBAR
              (WHADVP-1 (WRB:[1465..1468] how))
              (S
                (NP-SBJ (JJ:[1469..1474] other) (NNS:[1475..1481] agents))
                (VP (VBP:[1482..1491] stimulate)
                  (NP (NN:[1492..1507] steroidogenesis))
                  (ADVP-1 (-NONE-:[1507..1507] *T*))
                  (PRN (-LRB-:[1508..1509] -LRB-)
                    (PP
                      (ADVP (RB:[1509..1521] particularly))
                      (IN:[1522..1524] in)
                      (NP
                        (NP (DT:[1525..1528] the) (NNS:[1529..1534] areas))
                        (PP (IN:[1536..1538] of)
                          (NP
                            (NP (NN:[1539..1546] protein)
                                (NN:[1547..1556] synthesis))
                            (,:[1556..1557] ,)
                            (NP (NN:[1558..1565] protein)
                                (NN:[1566..1581] phosphorylation))
                            (,:[1581..1582] ,) (CC:[1583..1586] and)
                            (NP (NN:[1587..1598] cholesterol)
                                (NNS:[1599..1608] movements))))))
                    (-RRB-:[1608..1609] -RRB-)))))))))
    (VP (MD:[1610..1614] will)
      (VP (VB:[1616..1623] further)
        (NP (DT:[1624..1628] this) (NN:[1629..1642] understanding))))
    (.:[1642..1643] .)))

;section 15 Span:1647..1665
;Publication Types:
(SEC
  (FRAG (NNP:[1647..1658] Publication) (NNP:[1659..1664] Types)
        (::[1664..1665] :)))

;section 16 Span:1671..1677
;Review
(SEC
  (FRAG (NNP:[1671..1677] Review)))

;section 17 Span:1681..1725
;PMID: 3015692 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1681..1685] PMID) (::[1685..1686] :) (CD:[1687..1694] 3015692)
        (NN:[1695..1696] -LSB-) (NNP:[1696..1702] PubMed) (::[1703..1704] -)
        (NN:[1705..1712] indexed) (IN:[1713..1716] for)
        (NNP:[1717..1724] MEDLINE) (token:[1724..1725] -RSB-)))
